Wellbutrin Articles
Teva/Impax generic Wellbutrin XL 300mg pulled from US market on non-bioequivalence grounds
4 October 2012
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GSK and Nabi in deal for NicVAX, with upfront and potential payments of over $500 million
17 November 2009
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
GSK sells US Wellbutrin rights for $510M
6 May 2009
Actavis gets FDA appro for 150mg bupropion
8 December 2008
Final FDA appro for Watson's generic Wellbutrin
1 December 2008
Actavis opens R&D laboratory in Florida
10 November 2008
Teva's 2nd-qtr 2008 profit up 5% to $539M
18 August 2008
FDA questions switch to Teva's Bupropion
28 April 2008
Actavis' generic Wellbutrin and Zyban approved
7 April 2008
US drug prices before elections provokes voter ire
3 March 2008
Watson swings to profit of $38.4M in 4th qtr
3 March 2008
Watson's 3rd-qtr 2007 revenue hits $594.7M
19 November 2007
Stock Commentary - New York week to June 18, 2007
25 June 2007
Watson's generic Welbutrin cleared by FDA
25 June 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Watson gets $35M in GSK patent settlement
19 February 2007
Stock Commentary - New York week to Feb 12, 2007
19 February 2007
Patent expiries will stem growth of antidepressants market
18 December 2006
Pfizer launches Champix in the UK
11 December 2006
Pfizer's Champix approved in Europe
9 October 2006
FDA citizen petitions 'abused' by drug firms
17 July 2006
US FDA approves GSK's Wellbutrin for SAD
19 June 2006
Biovail's 2005 revenue reaches $936M
3 April 2006
Canada: branded drugs slip, generics grow
27 March 2006
US FDA posts DSOB meeting summary
15 August 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
Watson Pharma's EPS tops analysts' hopes
21 February 2005
Anchem submits US ANDA for Wellbutrin XL
22 November 2004
Biovail revises full-year outlook on robust sales
20 September 2004
GSK's 2nd-qtr 2004 EPS drops 12%
2 August 2004
GSK's 1st-qtr profit continues decline
10 May 2004
Approvals and launches of generic bupropion
29 March 2004
Green light for 150mg Wellbutrin generics
29 March 2004
Biovail revises 2004 guidance
15 March 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
Eon Labs starts shipping bupropion
26 January 2004
GSK exercises option for Biovail's Wellbutrin XL
15 December 2003
GlaxoSmithKline reports 24% 3rd qtr earnings growth
27 October 2003
Biovail stock recovers ground as investors return to calm
20 October 2003
Stock Commentary - Europe
6 October 2003
GSK gets boost from antidepressant ruling
29 September 2003
New indications for three GlaxoSmithKline products
8 September 2003
GSK 2nd-qtr earnings beat forecasts
28 July 2003
GSK's Wellbutrin XL on track for approval
7 July 2003
Varenicline, another Pfizer blockbuster?
30 June 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
Biovail's cold sore cream cleared by FDA
13 January 2003
Australian Pharma sales up 15%
5 August 2002
FDA clears new Wellbutrin SR dose
24 June 2002
Strong quarter for Canada's Biovail
6 May 2002
NICE says GSK's Zyban OK for use on NHS
15 April 2002
UK NICE's proposed guidance timetable
25 March 2002
Australian pharma ad tax breaks slammed
18 March 2002
GSK to appeal bupropion ruling
11 March 2002
EMEA sets up enquiry into GSK's Zyban
4 March 2002
GSK reports weight loss with bupropion
4 March 2002
GlaxoSmithKline 2001 pretax exceeds forecasts
18 February 2002
GSK plans six product filings in 2002
18 February 2002
GSK boosted by US Advair COPD decision
28 January 2002
Biovail and GSK sign $133 million marketing deal for bupropion
29 October 2001
Zyban helps smokers with CVD
21 September 2001
Pharmacia slams price of Celebrex in Australia
25 June 2001
Australian PBS must be more transparent: govt
5 June 2001
Zyban warnings are strengthened in UK
1 June 2001
Zyban safety fears resurface in UK
27 April 2001
US HMOs reveal their most-accepted drugs
5 April 2001
Director quits GSK over tobacco company links
15 March 2001
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
